Private Market View

MICRON Biotech

Chengdu, China · Founded 2022 · Privately Held (backing)

Last price · $/share
Implied valuation
Total raised
Last round

Key facts

  • Notable investors include Chengdu Venture Capital Group, Sichuan Development Fund, Chengdu Bio-Town Investment, BioTrack Capital, Sinopharm CICC.
  • Status: Privately Held (backing).
Free account
See the evidence behind this price
  • ·The complete investor list — 5 names
  • ·Watchlist + deal alerts for MICRON Biotech
  • ·The full record, as it builds
Create free account
No card required

Funding rounds

No rounds on record

No funding rounds for MICRON Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

About MICRON Biotech

Developer and provider of microfluidic technology intended for medical use. The company's technology is applied to three segments of medical aesthetics, drug delivery, and nuclear medicine and enables researchers to realize the adjustable and controllable particle size, structure and function with many application fields, including medical and health, material purification, phase change energy storage and electronic information, providing the healthcare industry with more previse methods of administering and creating novel drugs and therapies.

Sector
Healthcare
HQ
Chengdu, China
Founded
2022
Employees
60
Ownership
Privately Held (backing)
PA Mark — not yet priced

MICRON Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.

Recorded secondary trades

No prints on record

No secondary trades in MICRON Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

No fund marks yet

No SEC-registered fund has reported a fair-value mark on MICRON Biotech in its N-PORT filings yet. We sweep new filings monthly.

Pro members can request priority coverage with a 48-hour turnaround.